What is ADIL (ADIL) stock price today?

ADIL (ADIL) is currently trading at $3.33, up 1.22% today.

What is ADIL P/E ratio?

ADIL's P/E ratio is -1.14. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is ADIL return on equity (ROE)?

ADIL's return on equity (ROE) is -265.94%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is ADIL's market cap?

ADIL has a market capitalization of $3.20M.

NASDAQ · Biotechnology

ADIL (ADIL) Stock

$3.33 +1.22% NASDAQ: ADIL Healthcare

Valuation

Metric	Value
Price	$3.33
Market Cap	$3.20M
P/E Ratio	-1.14
P/B Ratio	1.16
P/S Ratio	0.00
EPS (TTM)	$-2.60
52-Week High	$19.00
52-Week Low	$1.31
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-265.94%
ROA	-1.11%
ROCE	-160.00%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	6.00

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-19.0M	$-11.0M	$-7.0M	$-8.0M	$-8.0M
Net Profit	$-19.0M	$-13.0M	$-7.0M	$-13.0M	$-8.0M
EPS	$-653.00	$-299.50	$-136.00	$-17.75	$-11.93
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$8.0M	$6.0M	$5.0M	$5.0M	$7.0M
Total Liabilities	$4.0M	$2.0M	$1.0M	$1.0M	$2.0M
Cash	$6.0M	$4.0M	$3.0M	$4.0M	$6.0M
Borrowings	$0	$0	$0	$0	$0

Latest News

Adial Pharmaceuticals Closes First $32 Million Tranche of Financing MT Newswires · Jun 16, 2026 Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing GlobeNewswire · Jun 16, 2026 Sector Update: Healthcare Stocks Higher Late Afternoon MT Newswires · Jun 11, 2026 Sector Update: Healthcare MT Newswires · Jun 11, 2026 Top Midday Gainers MT Newswires · Jun 11, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-12.0M	$-11.0M	$-7.0M	$-7.0M	$-6.0M
Investing Cash Flow	$0	$0	$8.0M	$0	$0
Financing Cash Flow	$2.0M	$0	$0	$4.0M	$0
Net Cash Flow	$2.0M	$-2.0M	$-1.0M	$1.0M	$2.0M
Free Cash Flow	$-12.0M	$-11.0M	$0	$-7.0M	$-6.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	-2.89
EV / EBITDA	-0.20
FCF Yield	-238.38%
Quick Ratio	3.18
Interest Coverage	—
Return 1Y	-70.59%
Return 3Y	-98.45%
Return 5Y	-99.83%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACXP	$1.40	-1.40%	-0.36	$2.22M	0.00%
APRE	$0.62	-1.16%	-0.47	$4.06M	0.00%
BCDABioCardia, Inc.	$0.84	-1.11%	-0.83	$4.88M	0.00%
BCLIBrainstorm Cell Therapeutics Inc.	$0.98	+6.52%	-1.04	$10.81M	0.00%
CDIO	$1.62	+4.52%	-0.53	$3.35M	0.00%

About ADIL

ADIL is led by CEO Cary John Claiborne, employs 5 people, headquartered in US, publicly traded since 2018.

ADIL stock trades at $3.33 with a market capitalization of $3.20M. The stock is valued at a price-to-earnings (P/E) ratio of -1.14, price-to-book of 1.16, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.31 and $19.00, and currently trades 82.5% below its 52-week high.

On profitability, ADIL generates a return on equity (ROE) of -265.94%, return on capital employed of -160.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides